4-Iodo-SAHA (1k), an orally active inhibitor of both class I and class II histone deacetylase (HDAC), exhibits EC50 values of 1.1, 0.95, 0.12, 0.24, 0.85, and 1.3 μM for Skbr3, HT29, U937, JA16, and HL60 cell lines, respectively. This compound holds potential for cancer research purposes [1].

4-Iodo-SAHA (1k) (0.1-100 μM; 48 h ) inhibits Skbr3, HT29, U937, JA16 and HL60 cell lines [1]. In SKBR3 cells, 4-Iodo-SAHA (1k) (2 μM; 6-24 h ) also affects acetylated H4 and p21 levels [1]. Cell Proliferation Assay [1] Cell Line: SKBR3, HT29, U937, JA16 and HL60 cell lines Concentration: 0.1-100 μM Incubation Time: 48 h Result: Inhibited SKBR3, HT29, U937, JA16 and HL60 cell lines with EC 50 s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM, respectively. Showed 10-fold potent as an inhibitor of U937 cell line compared to SAHA. Western Blot Analysis [1] Cell Line: SKBR3-breast-derived cell line Concentration: 2 μM Incubation Time: 6, 12 and 24 h Result: Time-dependently up regulated histone H4 acetylation and p21/WAF1 cell cycle inhibitor accumulation in SKBR3 cells.

4-Iodo-SAHA (1k) (50 mg/kg; p.o. five times a week for two weeks) has similar toxicity compared to SAHA-treated and control mice [1]. Animal Model: 8-week-old fvb mice [1] Dosage: 50 mg/kg Administration: Oral gavage; 50 mg/kg five times per week; for 2 weeks Result: Compared to both SAHA-treated and control mice with similar body weights and hematological counts.